Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 298

1.

Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer.

Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T.

Sci Rep. 2019 Aug 19;9(1):12071. doi: 10.1038/s41598-019-48600-8.

2.

Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.

Konishi S, Hatakeyama S, Numakura K, Narita S, Inoue T, Saito M, Tokui N, Yamamoto H, Yoneyama T, Hashimoto Y, Yoshikawa K, Narita S, Kawaguchi T, Habuchi T, Ohyama C.

Clin Genitourin Cancer. 2019 Jul 20. pii: S1558-7673(19)30222-8. doi: 10.1016/j.clgc.2019.07.006. [Epub ahead of print]

PMID:
31416753
3.

Efficacy of anti-PD-1 antibody nivolumab in Japanese patients with metastatic renal cell carcinoma: A retrospective multicenter analysis.

Numakura K, Horikawa Y, Kamada S, Koizumi A, Nara T, Chiba S, Kanda S, Saito M, Narita S, Inoue T, Shimoda N, Habuchi T.

Mol Clin Oncol. 2019 Sep;11(3):320-324. doi: 10.3892/mco.2019.1887. Epub 2019 Jun 25.

4.

Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.

Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, Terada N, Kobayashi T, Yamasaki T, Inoue T, Tsuchiya N, Ohyama C, Arai Y, Habuchi T, Morita S, Ogawa O.

Eur Urol Oncol. 2019 May;2(3):320-328. doi: 10.1016/j.euo.2018.10.011. Epub 2018 Nov 23.

PMID:
31200847
5.

Peri-operative efficacy and long-term survival benefit of robotic-assisted radical cystectomy in septuagenarian patients compared with younger patients: a nationwide multi-institutional study in Japan.

Iwamoto H, Morizane S, Koie T, Shiroki R, Kawakita M, Gondo T, Matsumoto K, Habuchi T, Sunada H, Endo Y, Noma H, Takenaka A, Kanayama H.

Int J Clin Oncol. 2019 May 23. doi: 10.1007/s10147-019-01470-6. [Epub ahead of print]

PMID:
31123937
6.

Research Evidence on High-Fat Diet-Induced Prostate Cancer Development and Progression.

Narita S, Nara T, Sato H, Koizumi A, Huang M, Inoue T, Habuchi T.

J Clin Med. 2019 Apr 30;8(5). pii: E597. doi: 10.3390/jcm8050597. Review.

7.

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.

Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M.

JAMA Netw Open. 2019 Feb 1;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115.

8.

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.

Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, Ogawa O, Narita S, Habuchi T, Yamashita S, Mitsuzuka K, Arai Y, Kandori S, Kojima T, Nishiyama H, Kawamura Y, Shimizu Y, Terachi T, Sugi M, Kinoshita H, Matsuda T, Yamada Y, Yamamoto S, Hirama H, Sugimoto M, Kakehi Y, Sakurai T, Tsuchiya N.

BMC Cancer. 2019 Feb 15;19(1):156. doi: 10.1186/s12885-019-5342-9.

9.

Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.

Hamano I, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C.

World J Urol. 2019 Feb 7. doi: 10.1007/s00345-019-02664-3. [Epub ahead of print]

PMID:
30729312
10.

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.

Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI.

BMC Cancer. 2019 Jan 7;19(1):17. doi: 10.1186/s12885-018-5224-6.

11.

Impact of nutritional status on the prognosis of patients with metastatic hormone-naïve prostate cancer: a multicenter retrospective cohort study in Japan.

Okamoto T, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C.

World J Urol. 2018 Dec 4. doi: 10.1007/s00345-018-2590-2. [Epub ahead of print]

PMID:
30511214
12.

Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.

Narita S, Nara T, Kanda S, Numakura K, Saito M, Inoue T, Satoh S, Nanjo H, Tsuchiya N, Mitsuzuka K, Koie T, Kawamura S, Ohyama C, Tochigi T, Arai Y, Habuchi T.

Clin Genitourin Cancer. 2019 Feb;17(1):e113-e122. doi: 10.1016/j.clgc.2018.09.019. Epub 2018 Sep 27.

PMID:
30391137
13.

Can single positive core prostate cancer at biopsy be considered a low-risk disease?

Yamamoto H, Koie T, Ookubo T, Mitsuzuka K, Narita S, Inoue T, Kawamura S, Kato T, Tochigi T, Tsuchiya N, Habuchi T, Arai Y, Ohyama C.

Int Urol Nephrol. 2018 Oct;50(10):1829-1833. doi: 10.1007/s11255-018-1966-y. Epub 2018 Aug 20.

PMID:
30128924
14.

Incidence and location of positive surgical margin among open, laparoscopic and robot-assisted radical prostatectomy in prostate cancer patients: a single institutional analysis.

Koizumi A, Narita S, Nara T, Takayama K, Kanda S, Numakura K, Tsuruta H, Maeno A, Huang M, Saito M, Inoue T, Tsuchiya N, Satoh S, Nanjo H, Habuchi T.

Jpn J Clin Oncol. 2018 Aug 1;48(8):765-770. doi: 10.1093/jjco/hyy092.

PMID:
29931077
15.

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients.

Numakura K, Fujiyama N, Takahashi M, Igarashi R, Tsuruta H, Maeno A, Huang M, Saito M, Narita S, Inoue T, Satoh S, Tsuchiya N, Niioka T, Miura M, Habuchi T.

Oncotarget. 2018 May 18;9(38):25277-25284. doi: 10.18632/oncotarget.25423. eCollection 2018 May 18.

16.

Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer.

Sato H, Narita S, Tsuchiya N, Koizumi A, Nara T, Kanda S, Numakura K, Tsuruta H, Maeno A, Saito M, Inoue T, Satoh S, Nomura K, Habuchi T.

BMC Urol. 2018 May 8;18(1):32. doi: 10.1186/s12894-018-0353-4.

17.

Two years of bicalutamide monotherapy in patients with biochemical relapse after radical prostatectomy.

Okubo T, Mitsuzuka K, Koie T, Hoshi S, Matsuo S, Saito S, Tsuchiya N, Habuchi T, Ohyama C, Arai Y; Michinoku Urological Cancer Study Group.

Jpn J Clin Oncol. 2018 Jun 1;48(6):570-575. doi: 10.1093/jjco/hyy060.

PMID:
29718346
18.

Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.

Komine N, Satoh S, Saito M, Numakura K, Inoue T, Tsuruta H, Narita S, Komatsuda A, Nanjo H, Kagaya H, Niioka T, Miura M, Mitobe Y, Habuchi T.

Int Immunopharmacol. 2018 May;58:57-63. doi: 10.1016/j.intimp.2018.03.004. Epub 2018 Mar 15.

PMID:
29550576
19.

Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.

Kagaya H, Niioka T, Saito M, Inoue T, Numakura K, Yamamoto R, Akamine Y, Habuchi T, Satoh S, Miura M.

Int J Mol Sci. 2018 Mar 16;19(3). pii: E882. doi: 10.3390/ijms19030882.

20.

A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study.

Inoue T, Miyazaki J, Ichioka D, Narita S, Kageyama S, Sugimoto M, Mitsuzuka K, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Matsui Y, Fujie K, Habuchi T, Nishiyama H.

BMC Cancer. 2018 Mar 14;18(1):290. doi: 10.1186/s12885-018-4186-z.

Supplemental Content

Loading ...
Support Center